Home > Publications Database > Association of oxidative stress and inflammatory metabolites with Alzheimer’s disease cerebrospinal fluid biomarkers in mild cognitive impairment > print

001     271075
005     20240811004513.0
024 7 _ |a pmid:39080778
|2 pmid
024 7 _ |a 10.1186/s13195-024-01542-4
|2 doi
024 7 _ |a pmc:PMC11287840
|2 pmc
024 7 _ |a altmetric:165810704
|2 altmetric
037 _ _ |a DZNE-2024-00947
082 _ _ |a 610
100 1 _ |a Ahmad, Shahzad
|b 0
245 _ _ |a Association of oxidative stress and inflammatory metabolites with Alzheimer’s disease cerebrospinal fluid biomarkers in mild cognitive impairment
260 _ _ |a London
|c 2024
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1723110465_2211
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Isoprostanes and prostaglandins are biomarkers for oxidative stress and inflammation. Their role in Alzheimer's disease (AD) pathophysiology is yet unknown. In the current study, we aim to identify the association of isoprostanes and prostaglandins with the Amyloid, Tau, Neurodegeneration (ATN) biomarkers (Aβ-42, p-tau, and t-tau) of AD pathophysiology in mild cognitive impairment (MCI) subjects.Targeted metabolomics profiling was performed using liquid chromatography-mass spectrometry (LCMS) in 147 paired plasma-CSF samples from the Ace Alzheimer Center Barcelona and 58 CSF samples of MCI patients from the Mannheim/Heidelberg cohort. Linear regression was used to evaluate the association of metabolites with CSF levels of ATN biomarkers in the overall sample and stratified by Aβ-42 pathology and APOE genotype. We further evaluated the role of metabolites in MCI to AD dementia progression.Increased CSF levels of PGF2α, 8,12-iso-iPF2α VI, and 5-iPF2α VI were significantly associated (False discovery rate (FDR) < 0.05) with higher p-tau levels. Additionally, 8,12-iso-iPF2α VI was associated with increased total tau levels in CSF. In MCI due to AD, PGF2α was associated with both p-tau and total tau, whereases 8,12-iso-iPF2α VI was specifically associated with p-tau levels. In APOE stratified analysis, association of PGF2α with p-tau and t-tau was observed in only APOE ε4 carriers while 5-iPF2α VI showed association with both p-tau and t-tau in APOE ε33 carriers. CSF levels of 8,12- iso-iPF2α VI showed association with p-tau and t-tau in APOE ε33/APOE ε4 carriers and with t-tau in APOE ε3 carriers. None of the metabolites showed evidence of association with MCI to AD progression.Oxidative stress (8,12-iso-iPF2α VI) and inflammatory (PGF2α) biomarkers are correlated with biomarkers of AD pathology during the prodromal stage of AD and relation of PGF2α with tau pathology markers may be influenced by APOE genotype.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Alzheimer Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Oxidative Stress: physiology
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a tau Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Peptide Fragments: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Isoprostanes: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Inflammation: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Metabolomics: methods
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Prostaglandins: cerebrospinal fluid
|2 MeSH
650 _ 7 |a APOE
|2 Other
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a Cerebrospinal fluid
|2 Other
650 _ 7 |a Isoprostane
|2 Other
650 _ 7 |a Mild cognitive impairment
|2 Other
650 _ 7 |a Oxidative stress
|2 Other
650 _ 7 |a Prostaglandin
|2 Other
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a Peptide Fragments
|2 NLM Chemicals
650 _ 7 |a Isoprostanes
|2 NLM Chemicals
650 _ 7 |a amyloid beta-protein (1-42)
|2 NLM Chemicals
650 _ 7 |a Prostaglandins
|2 NLM Chemicals
700 1 _ |a Yang, Wei
|b 1
700 1 _ |a Orellana, Adelina
|b 2
700 1 _ |a Frölich, Lutz
|b 3
700 1 _ |a de Rojas, Itziar
|b 4
700 1 _ |a Cano, Amanda
|b 5
700 1 _ |a Boada, Mercè
|b 6
700 1 _ |a Hernández, Isabel
|b 7
700 1 _ |a Hausner, Lucrezia
|b 8
700 1 _ |a Harms, Amy C.
|b 9
700 1 _ |a Bakker, Margot H. M.
|b 10
700 1 _ |a Cabrera-Socorro, Alfredo
|b 11
700 1 _ |a Amin, Najaf
|b 12
700 1 _ |a Ramírez, Alfredo
|0 P:(DE-2719)2812825
|b 13
|u dzne
700 1 _ |a Ruiz, Agustín
|b 14
700 1 _ |a Van Duijn, Cornelia M.
|b 15
700 1 _ |a Hankemeier, Thomas
|b 16
773 _ _ |a 10.1186/s13195-024-01542-4
|g Vol. 16, no. 1, p. 171
|0 PERI:(DE-600)2506521-X
|n 1
|p 171
|t Alzheimer's research & therapy
|v 16
|y 2024
|x 1758-9193
856 4 _ |u https://pub.dzne.de/record/271075/files/DZNE-2024-00947%20SUP1.docx
856 4 _ |u https://pub.dzne.de/record/271075/files/DZNE-2024-00947%20SUP2.xlsx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/271075/files/DZNE-2024-00947.pdf
856 4 _ |u https://pub.dzne.de/record/271075/files/DZNE-2024-00947%20SUP1.doc
856 4 _ |u https://pub.dzne.de/record/271075/files/DZNE-2024-00947%20SUP1.odt
856 4 _ |u https://pub.dzne.de/record/271075/files/DZNE-2024-00947%20SUP1.pdf
856 4 _ |u https://pub.dzne.de/record/271075/files/DZNE-2024-00947%20SUP2.csv
856 4 _ |u https://pub.dzne.de/record/271075/files/DZNE-2024-00947%20SUP2.ods
856 4 _ |u https://pub.dzne.de/record/271075/files/DZNE-2024-00947%20SUP2.xls
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/271075/files/DZNE-2024-00947.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:271075
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2812825
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-19
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-19
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS RES THER : 2022
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:09:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:09:21Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-19
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-19
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-19
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-19
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ALZHEIMERS RES THER : 2022
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-19
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2023-04-12T15:09:21Z
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies Bonn ; Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011101
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21